Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary
Future Oncology · 2023
DOI: 10.2217/fon-2022-1296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Joe M O'Sullivan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Queen University, Belfast, United Kingdom. Hauptthemen laut MEDLINE: Bone Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant, Radium. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer Corporation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
WHAT IS THIS SUMMARY ABOUT?: Few life-prolonging treatment options are available for patients with metastatic castration-resistant prostate cancer (mCRPC). This article provides an overview of the current systemic treatments available for mCRPC and reviews studies that investigate the optimal timing for the use of radium-223. The aim is to illustrate possible systemic treatment sequences to maximize benefit from radium-223 therapy. WHAT IS METASTATIC CASTRATION-RESISTANT PROSTATE CANCER & HOW IS IT TREATED?: Prostate cancer is called mCRPC when it spreads to organs outside of the prostate (such as the lymph nodes, bones, liver, or lungs) and no longer responds to hormonal therapy. There are several treatment options available for mCRPC, such as abiraterone, enzalutamide, radium-223, docetaxel, cabazitaxel, olaparib, rucaparib, sipuleucel-T, and 177Lu-PSMA. It is important to understand the risks and benefits associated with each treatment and whether current use may have an impact on future treatment options, including eligibility in certain clinical trials. Maintaining bone health is also an important part of prostate cancer care. WHAT IS RADIUM-223?: Radium-223 is a radioactive molecule that releases strong radiation within a very small range around itself. It mainly travels to the bone where the prostate cancer has spread and kills the cancer cells in that area. Results from a clinical study named ALSYMPCA showed that men who received radium-223 lived longer in addition to having less bone pain. The most common side effects of radium-223 are nausea, vomiting, and diarrhea. Radium-223 minimally suppresses the bone marrow, which means that it slightly reduces the levels of red and white blood cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Queen University, Belfast, United Kingdom.
- Private Practice, Elliot Abramowitz, Ph.D, Long Beach, NY.
- Retired Member of the Board of Directors, Answer Cancer Foundation.
Förderung
- Bayer Corporation
Zitieren
APA
O'Sullivan, J. M., Abramowitz, E., & Sierra-Scacalossi, L. (2023). Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary. Future Oncology. https://doi.org/10.2217/fon-2022-1296
Vancouver
O'Sullivan JM, Abramowitz E, Sierra-Scacalossi L. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary. Future Oncology. 2023. doi:10.2217/fon-2022-1296
BibTeX
@article{OSullivan2023,
author = {O'Sullivan, Joe M and Abramowitz, Elliot and Sierra-Scacalossi, Len},
title = {Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary},
journal = {Future Oncology},
year = {2023},
doi = {10.2217/fon-2022-1296}
}
EUVIMED